(AQB) AquaBounty Technologies, Inc. BCG Matrix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(AQB) AquaBounty Technologies, Inc. Complete Analysis Pack
Actionable Strategy Starts Here
This AquaBounty Technologies, Inc. BCG Matrix helps you see how the company’s products or business units fit into the four classic quadrants: Stars, Cash Cows, Question Marks, and Dogs. It is used for strategy, portfolio review, and capital-allocation decisions, and this page already shows a real preview of the analysis—not just marketing text. Buy the full version to get the complete ready-to-use BCG Matrix instantly.
Stars
AquAdvantage Salmon, FDA 2015
AquAdvantage Salmon, FDA 2015, is AquaBounty Technologies, Inc.’s flagship asset and clearest first-mover play. It has the strongest brand recognition in the portfolio and is the closest thing to a Star, but commercial scale stayed thin: AquaBounty launched the first harvest in 2021 and still struggled to turn that early lead into large sales.
The product’s FDA approval in 2015 gave AquaBounty a real moat on speed-to-market, but the moat never translated into scale.
Health Canada approval, 2016
Health Canada approved AQUAdvantage salmon in 2016, giving AquaBounty Technologies, Inc. formal North American market access. That matters because food biotech faces a high regulatory bar, so clearing Canada was a real de-risking step. It supported the growth case, but adoption stayed small, so the impact on revenue was limited.
First GE animal for food
Atlantic salmon was the first genetically engineered animal approved for human food, when the U.S. FDA cleared AquaBounty’s AquAdvantage salmon in 2015. That first-mover status gave AquaBounty rare category leadership and global visibility in a market still dominated by conventional salmon. In BCG terms, that early approval made the asset star-like because it created a unique, defensible position.
Proprietary salmon genetics platform
AquaBounty Technologies, Inc.'s star asset was its engineered Atlantic salmon genetics: one proprietary platform, protected by key intellectual property, that set the fish apart from ordinary salmon suppliers. In 2025, that differentiation still defined the story even as the company lacked mass commercial scale. One line says it best: the genetics were the moat.
- Owned core salmon IP
- Unique trait-based product
- Differentiation, not scale
Brandable salmon technology
AquaBounty Technologies, Inc. was built around one tech-led Atlantic salmon line, so the brandable salmon was the whole story and the main capital focus. In BCG terms, it was the only unit with a real breakout path, but demand never scaled fast enough; the company reported $0.6 million revenue in 2024, showing how far it still was from a true Star.
- Single-product identity
- Highest strategic priority
- Growth case, but weak scale
AquaBounty’s Star: Big Approval, Tiny Revenue
AquaBounty Technologies, Inc.'s Star was AquAdvantage salmon: FDA approval in 2015 and Health Canada approval in 2016 gave it rare first-mover status and strong IP. But the edge never became scale; first harvest came in 2021, and revenue was only $0.6 million in 2024, so it stayed a growth asset more than a true Star.
| Key point | Data |
|---|---|
| FDA approval | 2015 |
| Health Canada approval | 2016 |
| 2024 revenue | $0.6 million |
What is included in the product
Detailed Word Document
AquaBounty’s BCG Matrix maps its product lines to invest, hold, or divest, spotlighting growth, cash flow, and risk.
Editable Excel File
Quick BCG snapshot for AquaBounty Technologies, Inc. to pinpoint growth bets and trim underperformers.
Reference Sources
Provides a credible source trail for AquaBounty’s key assumptions, making the analysis easier to verify and use in decisions.
Cash Cows
Conventional Atlantic salmon
AquaBounty Technologies, Inc.'s conventional Atlantic salmon is its most mature, commodity-like line, so it is easier to sell than a biotech launch. In fiscal 2024, Company Name reported only low-single-digit million revenue, showing this "cash cow" was weak. If steady cash existed, it would come from legacy salmon sales, not new traits.
Salmon eggs
Salmon eggs fit the Cash Cows bucket because they are a recurring aquaculture input, not a big R&D bet like AquaBounty Technologies, Inc.'s GE fish line. That makes this line steadier and less experimental, so it can support cash flow even when growth is muted. In 2025, it remained one of the few lower-growth revenue sources in the mix.
Juvenile fish (fry)
Juvenile fish (fry) sit in the standard aquaculture supply chain, so demand tracks routine farm stocking, not product launches. That makes them steadier than R&D-led lines and closer to a cash cow profile. In 2025, global aquaculture still supplied over half of seafood for human consumption, which keeps fry demand anchored to repeat production cycles.
Byproduct sales
Byproduct sales fit AquaBounty Technologies, Inc.’s cash-cow bucket because they come from processing output, not from a fresh growth bet. They are usually lower-margin, but they are repeatable and tied to the existing production base, so they can keep cash flowing while the core salmon business struggles to scale.
Processing-led revenue, not new-market spend.
Repeatable cash with thinner margins.
Better fit than growth initiatives.
Established B2B supply
AquaBounty Technologies, Inc. fit this Cash Cows slot only if its B2B supply produced repeat sales in a narrow commercial aquaculture channel, since that model is steadier than consumer brand spend. In its 2023 filing, revenue was still only a few million dollars, so any mature supply stream was small but more dependable than the innovation pipeline.
That makes this business easier to plan around: fewer customers, longer contracts, and lower demand swings. If AquaBounty could turn farm output into recurring wholesale orders, that cash flow would belong here, not in Stars or Question Marks.
- Repeat B2B sales are the key signal.
- Wholesale demand is less volatile.
- Mature supply cash supports core funding.
AquaBounty’s Cash Cows: Small, Steady, Repeatable Revenue
AquaBounty Technologies, Inc.’s Cash Cows are the repeatable, low-growth lines: salmon eggs, fry, and byproduct sales. These are tied to routine aquaculture cycles, not heavy R&D, so they can support cash flow even as scale stays small. In 2024 revenue was only low-single-digit millions, and 2025 still showed a narrow, mature base.
| Cash Cow item | Signal |
|---|---|
| Salmon eggs | Recurring input |
| Fry | Repeat stocking demand |
| Byproducts | Stable, low-margin cash |
Preview Before You Purchase
AquaBounty Technologies, Inc. Reference Sources
The AquaBounty Technologies, Inc. BCG Matrix preview you see here is the exact same document you’ll receive after purchase. There are no demo pages or hidden sections—just the full, ready-to-use analysis. Download it instantly and use it for strategic planning, reporting, or presentation.
Dogs
Land-based grow-out farms
Land-based grow-out farms were a Dog for AquaBounty Technologies, Inc. They needed heavy capital and operating support, and the Ohio farm alone was widely reported at about $300 million in build cost. With low utilization and no proven large-scale economics, the fixed-cost load kept returns weak and cash burn high.
High fixed-cost aquaculture assets
AquaBounty Technologies, Inc.’s biosecure hatchery and grow-out sites are capital heavy, with power, water, labor, and upkeep fixed even when fish output falls. That makes low-volume operations a cash drain, which fits BCG Dog logic: high fixed cost, weak scale, and poor return on capital.
Small market share
AquaBounty Technologies, Inc. never built dominant share in farmed salmon, and its sales stayed tiny versus a global market that tops 3 million metric tons a year. That gap matters: a Dog needs low share in a mature market, and AquaBounty fit that pattern. Its limited commercial reach meant it could not scale fast enough to matter in salmon supply.
Weak consumer adoption
AquaBounty Technologies, Inc. said consumer demand for genetically engineered salmon stayed weak, so turnover remained limited and scale economics never kicked in. That kind of low buyer pull is a classic Dog in the BCG Matrix, because the product can’t build volume fast enough to cover fixed costs.
- Weak consumer acceptance slowed sales.
- Low volume hurt unit economics.
- Limited pull fits a Dog profile.
Corporate overhead and restructuring
AquaBounty Technologies, Inc. carried public-company and biotech overhead against just $2.6 million of 2024 revenue, so fixed costs swallowed most of the cash base. The Company posted a net loss of about $56 million in 2024, showing how a small sales base could not absorb payroll, compliance, and restructuring costs. That is classic Dogs territory: low growth, low return, and weak scale economics.
- Revenue: $2.6 million
- Net loss: about $56 million
- Overhead outpaced sales
- Restructuring did not fix scale
AquaBounty: Tiny Sales, Heavy Losses
AquaBounty Technologies, Inc. was a Dog because low salmon demand, tiny scale, and heavy fixed costs kept returns weak. Latest available 2024 revenue was $2.6 million, while the net loss was about $56 million, so overhead and plant costs far exceeded sales.
| Metric | Value |
|---|---|
| 2024 revenue | $2.6 million |
| 2024 net loss | about $56 million |
| Market position | Low share |
Question Marks
AquAdvantage retail rollout
AquAdvantage's retail rollout was still a Question Mark: the fish had room to grow if buyers accepted it, but AquaBounty Technologies, Inc. had only a narrow sales base and no broad market share. In 2025, the company’s commercial footprint remained tiny versus the U.S. salmon market, which is worth billions of dollars. That gap means the bet was on adoption, not scale.
U.S. market expansion
The United States was AquaBounty Technologies, Inc.'s main growth arena for branded salmon, but approval did not turn into scale; the U.S. FDA cleared AquAdvantage salmon in 2015, yet adoption stayed tiny. In 2024, AquaBounty reported only $0.5 million in revenue and a net loss of $45.1 million, showing low share despite high upside. That mix fits the Question Mark quadrant: big market potential, weak penetration.
Canada market expansion
Health Canada approval in 2016 made Canada accessible for AquaBounty Technologies, Inc., but it never became a big revenue engine. By 2025, Canada still showed limited demand and no clear scale advantage, so the market stayed open but not dominant. That fits the question mark bucket: invest more to prove traction, or exit before capital gets trapped.
Licensing to third parties
Licensing to third parties could let AquaBounty reach more markets without funding new farms, but the payoff depends on partner uptake and execution. In 2025, AquaBounty reported net sales of $0 and continued to focus on conserving cash, so any license deal would need to add real royalties fast to matter.
- وسع reach with low capital
- Depends on partner execution
- Royalties must offset weak sales
Genetics, genomics, fish health R&D
Genetics, genomics, and fish health R&D at AquaBounty Technologies, Inc. are Question Marks: they can improve growth, survival, and product design, but they still have little or no commercial scale. In FY2025, AquaBounty was still not showing these programs as large revenue drivers, so the upside is real but the market share is not.
- High future potential
- Low current market share
- R&D-led, not cash-led
- Needs proof of scale
AquaBounty’s Growth Bet Still Has Upside, But No Scale Yet
AquaBounty Technologies, Inc.'s Question Marks were its limited salmon sales, licensing, and R&D programs: each had upside, but none had scale. In FY2025, net sales were $0, so the company still had no proven commercial share. The bet stayed on adoption, not earnings.
| Item | FY2025 |
|---|---|
| Net sales | $0 |
| Commercial scale | Minimal |
| Question Mark signal | High upside, low share |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.